Mellinghoff, I. K., Peters, K. B., Cloughesy, T. F., Burris, H. A. I. I. I., Maher, E. A., Janku, F., … Wen, P. Y. (2020). Vorasidenib (VOR; AG-881), an inhibitor of mutant IDH1 and IDH2, in patients (pts) with recurrent/progressive glioma: Updated results from the phase I non-enhancing glioma population. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 38).

Mellinghoff, Ingo K., Katherine B. Peters, Timothy Francis Cloughesy, Howard A. I. I. I. Burris, Elizabeth Anne Maher, Filip Janku, Gregory Michael Cote, et al. “Vorasidenib (VOR; AG-881), an inhibitor of mutant IDH1 and IDH2, in patients (pts) with recurrent/progressive glioma: Updated results from the phase I non-enhancing glioma population.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 38, 2020.

Mellinghoff IK, Peters KB, Cloughesy TF, Burris HAIII, Maher EA, Janku F, et al. Vorasidenib (VOR; AG-881), an inhibitor of mutant IDH1 and IDH2, in patients (pts) with recurrent/progressive glioma: Updated results from the phase I non-enhancing glioma population. In: JOURNAL OF CLINICAL ONCOLOGY. 2020.

Mellinghoff, Ingo K., et al. “Vorasidenib (VOR; AG-881), an inhibitor of mutant IDH1 and IDH2, in patients (pts) with recurrent/progressive glioma: Updated results from the phase I non-enhancing glioma population.” JOURNAL OF CLINICAL ONCOLOGY, vol. 38, no. 15, 2020.

Mellinghoff IK, Peters KB, Cloughesy TF, Burris HAIII, Maher EA, Janku F, Cote GM, De La Fuente MI, Clarke JL, Kha L, Li L, Man Y, Arnofsky M, Hassan I, Steelman L, Pandya SS, Wen PY. Vorasidenib (VOR; AG-881), an inhibitor of mutant IDH1 and IDH2, in patients (pts) with recurrent/progressive glioma: Updated results from the phase I non-enhancing glioma population. JOURNAL OF CLINICAL ONCOLOGY. 2020.